Danaher Corporation
Danaher Corporation (NYSE: DHR) is a global science and technology company with more than 15 operating companies serving biotechnology, life sciences and diagnostics markets. Its Biotechnology segment supplies equipment, consumables, software and services used to research and manufacture biological medicines, serving… From the company’s description.
In fiscal 2025, Danaher Corporation reported revenue of $24.57B, up 2.9% from fiscal 2024, and net income of $3.60B. Its operating margin was 19.1%, and operations generated $6.42B in cash. Over the twelve months to Sep 25, 2026, revenue was $25.61B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Danaher Corporation does
In the company’s own words
Danaher Corporation (NYSE: DHR) is a global science and technology company with more than 15 operating companies serving biotechnology, life sciences and diagnostics markets. Its Biotechnology segment supplies equipment, consumables, software and services used to research and manufacture biological medicines, serving pharmaceutical and biotechnology companies, research institutions and contract manufacturers. Life Sciences provides instruments, consumables, software and services for biological research, drug development and manufacturing, along with filtration products for industrial and food and beverage applications. Diagnostics offers clinical instruments, consumables, software and services used by hospitals, physicians’ offices, reference laboratories and other care settings to diagnose disease and guide treatment. The company markets products under brands including Cytiva, Pall, Beckman Coulter, Cepheid, Leica Microsystems, SCIEX and Radiometer. Its businesses sell primarily through direct sales teams and independent distributors to customers across a geographically diverse base. Danaher applies its Danaher Business System across its operating companies and has expanded its portfolio through acquisitions, including Pall, Cytiva and Cepheid. As of December 31, 2025, it had approximately 60,000 employees.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- WASHINGTON, DC
- Fiscal year end
- December
- CIK
- 313616
- SIC
- 3823
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Danaher Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Danaher Corporation · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Danaher Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Danaher Corporation’s bonds, as funds hold them
Funds report holding 13 issues of Danaher Corporation’s debt, $423.20M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.59%, maturing 2028 to 2051.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Danaher Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Danaher Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Danaher Corporation's last four quarterly filings that the numbers alone won't show?”